


Agreement for Receiving H9 or H9/HTLV-III_B Cell Line **MAY 25 Rec**

I have read and have agreed to adhere to the following guidelines for use of H9/HTLV-III_B:

1. Use of H9 or H9/HTLV-III_B will be limited to my immediate laboratory. I will not give it out without prior written approval from Dr. Gallo.

2. Work performed will be on a collaborative basis with Dr. Gallo, Dr. Popovic, Dr. Wong-Staal, and their colleagues (to be specified by them) for the specific purpose of studying expression of HTLV-LTR linked genes in these cells. No other experiments should be initiated with these cells without prior discussion with the above named people.



3. H9 or H9/HTLV-III_B will not be used for commercial purposes. A U.S. Government (National Cancer Institute) patent is in effect.

4. Use of the H9/HTLV-III_B line or virus produced from it will be according to U.S. Government recommendations (see attached). Work can be carried out in a biosafety level 2 facility if the equipment, techniques and access to the work area are maintained as biosafety level 3. Large scale production of the virus requires strict biosafety level 3 containment.

5. Any operations using the infected cell outside of biocontainment will be after treatment such as gluteraldehyde fixation.

Signature _____ Date _____

(Please type or print name and address below)

Dr. William A. Haseltine
Harvard Univ. Med. Schl.
Dana-Farber Cancer Inst.
44 Binney Street
Boston, Massachusetts 02115